TNGX
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
Article Summary
BUY- Tango Therapeutics Inc. (NASDAQ: TNGX) announced key leadership appointments adding three seasoned industry executives to support rapid advancement of vopimetostat, a highly potent and selective PRMT5 inhibitor, towards its first potential regulatory approval in pancreatic cancer.
- Matthew Gall was appointed Chief Financial Officer, Yen-Ching Chua as Chief Development Operations Officer, and Janice Kapty, PhD as SVP, Corporate Strategy and Project Leadership, with Gall succeeding Daniella Beckman as CEO, while Chua will oversee clinical operations including data management, quality, clinical compliance and clinical sourcing.
- Gall is a seasoned biotechnology executive with extensive finance, corporate development, strategic transaction and capital raising experience, having previously been Chief Financial officer at Kalaris Therapeutic and iTeos Therapeutics, and held finance, business development and corporate strategy roles at Sarepta Theraputics, Celgene Corporation and Gilead Sciences.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 48.3% | 25% | 95.0 ptsOutstanding (48.3%) - Very strong |
| EPS Growth Next 5Y ? | -25.8% | 25% | 0.0 ptsNegative (-25.8%) - Declining expectations |
| Target Price Upside ? | 8.5% | 20% | 10.0 ptsNear/At Target (8.5%) - Target: $22.30 vs Current: $24.36 |
| Gross Margin % ? | 96.3% | 15% | 100.0 ptsExceptional (96.3%) - Strong pricing power |
| Drawdown from 52-Wk High ? | 1.2% | 15% | 20.0 ptsBarely a Dip (1.2%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About TNGX
- Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
- The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
- It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer.
- The company was founded in 2017 and is headquartered in Boston, Massachusetts.